(NASDAQ: YS) Ys Biopharma Co's forecast annual revenue growth rate of -40.25% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 60.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.43%.
Ys Biopharma Co's revenue in 2024 is $560,758,801.On average, 1 Wall Street analysts forecast YS's revenue for 2025 to be $10,025,159,563, with the lowest YS revenue forecast at $10,025,159,563, and the highest YS revenue forecast at $10,025,159,563.
In 2026, YS is forecast to generate $18,629,320,457 in revenue, with the lowest revenue forecast at $18,629,320,457 and the highest revenue forecast at $18,629,320,457.